Figure 9.Fraxetin enhances the anti-tumor efficacy of gemcitabine and suppresses the oncogenesis and development of PDA via antagonizing STAT3 activation.
Figure 9 — The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation | Aging
